

Immunoglobulin Light Chains

Table of Content

- [Purpose](#)
- [Description & Definitions](#)
- [Criteria](#)
- [Coding](#)
- [Document History](#)
- [References](#)
- [Special Notes](#)
- [Keywords](#)

<u>Effective Date</u>	3/2022
<u>Next Review Date</u>	2/15/2024
<u>Coverage Policy</u>	Medical 333
<u>Version</u>	2

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member’s condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

Purpose:

This policy addresses Immunoglobulin light chains testing.

Description & Definitions:

Immunoglobulin light chains is a serum blood test to help diagnose or monitor plasma cell disorders (such as multiple myeloma and amyloidosis).

Criteria:

Immunoglobulin Light Chains testing is considered medically necessary for **1 or more of the following**:

- Monoclonal plasma cell proliferative disorder
- Systemic amyloidosis (AL)
- Multiple myeloma

Immunoglobulin Light Chains testing is considered **not medically necessary** for uses other than those listed in the clinical criteria, to include but not limited to:

- Iron Deficiency Anemia
- Peripheral Neuropathy

Coding:

Medically necessary with criteria:

Coding	Description
83521	Immunoglobulin light chains (ie, kappa, lambda), free, each

Considered Not Medically Necessary:

Coding	Description
	None

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2022: March February

Reviewed Dates:

- 2023: February

Effective Date:

- March 2022

References:

Including but not limited to: Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2022). Retrieved Jan 18, 2023, from Hayes, Inc:

<https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Immunoglobulin%2520light%2520chain%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522>

(2022, Aug 31). Retrieved Jan 18, 2023, from MCG: <https://careweb.careguidelines.com/ed26/index.html>

(2022). Retrieved Jan 19, 2023, from PubMed:

<https://pubmed.ncbi.nlm.nih.gov/?term=immunoglobulin+light+chains&filter=years.2022-2022>

(2023). Retrieved Jan 18, 2023, from Centers for Medicare and Medicaid Services:

<https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=Immunoglobulin+light&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all>

(2023). Retrieved Jan 19, 2023, from Department of Medical Assistance Services:

<https://vamedicaid.dmas.virginia.gov/global-search?keys=light+chains>

CLINICAL GUIDELINES GENETIC TESTING. (2023). Retrieved Jan 18, 2023, from AIM Specialty Health:

<https://aimspecialtyhealth.com/resources/clinical-guidelines/genetic-testing/>

Dispenzieri, A. (2022, Apr 14). Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis. Retrieved Jan 18, 2023, from UpToDate: https://www.uptodate.com/contents/clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis?search=Immunoglobulin%20light%20chains&topicRef=6666&source=see_link#H8

Free Light Chains. (2021, Sep 13). Retrieved Jan 19, 2023, from MedlinePlus: <https://medlineplus.gov/lab-tests/free-light-chains/>

PART 866 -- IMMUNOLOGY AND MICROBIOLOGY DEVICES - Subpart F - Immunological Test Systems. (2022, Nov 29). Retrieved Jan 19, 2023, from Food and Drug Administration:
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=866.5550>

Product Classification. (2023, Jan 16). Retrieved Jan 19, 2023, from U.S. Food and Drug Administration:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpdc/classification.cfm?start_search=1&Submission_Type_ID=&DeviceName=&ProductCode=&DeviceClass=&ThirdParty=B&Panel=IM&RegulationNumber=866%2E5510&Implant_Flag=&Life_Sustain_Support_Flag=&PAGENUM=100&sort

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to be medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*

Keywords:

SHP Immunoglobulin light chains, SHP Medical 333, Ig Kappa Light Chain Gene, Free Light Chains, Kappa, Kappa FLC, Kappa-Free Light Chain, Lambda, Lambda FLC, Lambda-Free Light Chain, Light Chains, Serum Free Light Chains, Monoclonal plasma cell proliferative disorder, Systemic amyloidosis, Multiple myeloma, Iron Deficiency Anemia